Ticagrelor Tablet
Product Images NDC 72205-406

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 72205-406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tica-tabs-90mg-1000s-cntnr-label (Tica Tabs 90mg 1000s Cntnr Label)

Label for Ticagrelor Tablets 90 mg oral tablets. The label states the product contains 90 mg ticagrelor per tablet and is packaged in a quantity of 1,000 tablets. The product is manufactured by MSN Laboratories Private Limited, India, and distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. The label includes storage information, a medication guide instruction, and barcodes.*

FDA Label Image

Tica-tabs-90mg-100s-cntnr-label (Tica Tabs 90mg 100s Cntnr Label)

Ticagrelor Tablets 90 mg label showing a package of 100 oral tablets. The label includes the NDC 72205-368-91 and states the medication is manufactured by MSN Laboratories Private Limited, India, and distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. It advises dispensing the medication guide with each patient.*

FDA Label Image

Tica-tabs-90mg-180s-cntnr-label (Tica Tabs 90mg 180s Cntnr Label)

Ticagrelor Tablets 90 mg oral tablets label indicating a package of 180 tablets. The label includes warnings, storage instructions, manufacturing by MSN Laboratories Pvt Ltd, and distribution by Novadoz Pharmaceuticals LLC. The label features the Novadoz logo and dosage guidance to dispense the accompanying Medication Guide.*

FDA Label Image

Tica-tabs-90mg-60s-cntnr-label (Tica Tabs 90mg 60s Cntnr Label)

Ticagrelor Tablets 90 mg oral tablets label showing a 60-tablet package. The label includes warnings, storage instructions, and manufacturer information from MSN Laboratories Private Limited, India. Distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. The label includes the NDC 72205-368-60 and a barcode.*

FDA Label Image

Tica-tabs-90mg-blister-foil (Tica Tabs 90mg Blister Foil)

Ticagrelor 90 mg tablet packaging label distributed by Novadoz Pharmaceuticals LLC. The label includes the proprietary name, strength (90 mg), dosage form (tablet), directions for dispensing (Rx Only), barcode, lot, expiration date placeholders, and states it is made in India. Revisions dated 03/2025 are noted.*

FDA Label Image

Tica-tabs-90mg-carton-label (Tica Tabs 90mg Carton Label)

Box label for Ticagrelor Tablets 90 mg oral tablets by Novadoz Pharmaceuticals LLC. The label indicates a quantity of 100 (10 x 10 Unit-Dose) tablets. The label includes warnings, storage instructions, manufacturer information (MSN Laboratories Private Limited, India), and a barcode. The NDC is 72205-368-06.*

FDA Label Image

Tica-tabs-fig-01 (Tica Tabs Fig 01)

Kaplan-Meier cumulative event curve comparing Ticagrelor 90 mg and Clopidogrel over 360 days from first study drug dose. The y-axis shows cumulative percentage of events, and the x-axis shows days. The chart includes patient numbers at risk and events for each treatment group.*

FDA Label Image

Tica-tabs-fig-02 (Tica Tabs Fig 02)

A bar chart comparing the percentage of patients who had an event following coronary artery bypass grafting (CABG) over several days. The chart uses two categories labeled T and C, with data presented as vertical bars for each day, including days 1 through 8 and greater than or equal to 8.*

FDA Label Image

Tica-tabs-fig-03 (Tica Tabs Fig 03)

A cumulative percentage line graph comparing events over months from randomization between Ticagrelor and Placebo groups. The x-axis represents time in months, while the y-axis shows cumulative percentage of events. Two lines indicate event rates for Ticagrelor (solid line) and Placebo (dashed line), with Ticagrelor showing higher cumulative events over time.*

FDA Label Image

Tica-tabs-fig-04 (Tica Tabs Fig 04)

A cumulative incidence plot comparing Ticagrelor 90 mg twice daily versus placebo over a period of 34 days. The chart displays cumulative event rates on the vertical axis and days from randomization on the horizontal axis, with data points indicating differences between the two groups.*

FDA Label Image

Tica-tabs-fig-05 (Tica Tabs Fig 05)

A line graph comparing the percent inhibition of platelet aggregation (IPA) over an 8-hour period for ticagrelor 180 mg, clopidogrel 600 mg, and placebo, showing ticagrelor with the highest and fastest IPA response among the three.*

FDA Label Image

Tica-tabs-fig-06 (Tica Tabs Fig 06)

A line graph comparing Platelet Aggregation Inhibition (PAI, %) induced by 20μM ADP over 10 days for Ticagrelor, Clopidogrel, and Placebo. An inset graph shows PAI induced by 20μM ADP over 48 hours. Ticagrelor and Clopidogrel demonstrate higher PAI compared to Placebo across both time scales.*

FDA Label Image

Tica-tabs-fig-07 (Tica Tabs Fig 07)

A forest plot chart showing the mean effect and 90% confidence intervals for Ticagrelor and AR-C124910XX across various intrinsic factors, including age, gender, ethnicity, renal impairment, end-stage renal disease, and hepatic impairment. The chart compares pharmacokinetic parameters Cmax and AUC relative to reference and provides dosing adjustment recommendations, all indicating no dose adjustment needed.*

FDA Label Image

Tica-tabs-fig-08 (Tica Tabs Fig 08)

A comparative chart showing the mean effect and 90% confidence intervals of various interacting drugs on Ticagrelor and AR-C124910XX. The horizontal axis represents change relative to reference values for PK parameters (Cmax and AUC). The chart includes recommendations such as avoiding concomitant use or no dose adjustment needed for each interacting drug listed.*

FDA Label Image

Tica-tabs-fig-09 (Tica Tabs Fig 09)

A chart showing the mean effect and 90% confidence interval of various doses of Ticagrelor on interacting drugs, including Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine. The x-axis represents change relative to interacting drug alone, with recommendations for dose adjustments listed to the right.*

FDA Label Image

Tica-tabs-fig-10 (Tica Tabs Fig 10)

A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg versus Clopidogrel over 360 days from randomization. The x-axis shows days from randomization, and the y-axis shows cumulative percentage of events. A legend box provides sample sizes, event percentages, and hazard ratios for both drugs.*

FDA Label Image

Tica-tabs-fig-11 (Tica Tabs Fig 11)

A forest plot comparing the hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus Clopidogrel across various patient characteristics and subgroups. The chart displays treatment effects overall, by geography, ASA dose, treatment approach, MI type, diabetes history, prior TIA/stroke, age groups, sex, and race. Squares represent HR estimates, and horizontal lines show confidence intervals, indicating whether Ticagrelor or Clopidogrel is favored.*

FDA Label Image

Tica-tabs-fig-12 (Tica Tabs Fig 12)

Data table comparing ticagrelor versus clopidogrel outcomes by region (US and non-US) and aspirin dose (>=300 mg, >100-<300 mg, <=100 mg), showing number of subjects, events, and hazard ratio with confidence intervals. A forest plot visualizes hazard ratios indicating relative treatment effects.*

FDA Label Image

Tica-tabs-fig-13 (Tica Tabs Fig 13)

A Kaplan-Meier cumulative incidence curve comparing event rates over time among three groups: Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo. The x-axis represents days from randomization, while the y-axis shows the cumulative percentage of events. A table of participants at risk at various time points and hazard ratios with confidence intervals and p-values is included.*

FDA Label Image

Tica-tabs-fig-14 (Tica Tabs Fig 14)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus Placebo across multiple patient subgroups. It includes factors like age, sex, race, body mass index, prior cardiovascular disease, time from qualifying MI, and other clinical characteristics, illustrating the relative treatment effects.*

FDA Label Image

Tica-tabs-fig-15 (Tica Tabs Fig 15)

A line graph showing cumulative percentage over months from randomization comparing Ticagrelor and placebo. The x-axis represents months from 0 to 54, and the y-axis shows cumulative percentage from 0% to 14%. Two lines depict events for Ticagrelor (solid line) and placebo (dashed line), with Ticagrelor showing slightly lower cumulative percentages. The graph includes numbers at risk below the x-axis for both groups at various time points.*

FDA Label Image

Tica-tabs-fig-16 (Tica Tabs Fig 16)

A forest plot chart displaying hazard ratios (HR) with 95% confidence intervals for various patient subgroups comparing Ticagrelor versus placebo in terms of outcomes. The Y-axis lists patient characteristics, and the X-axis shows the HR scale, where values less than 1 favor Ticagrelor and values greater than 1 favor placebo. The chart includes data on age, sex, race, body mass index, region, aspirin dose, HbA1c levels, insulin use, history of angina, coronary artery disease, time since recent percutaneous coronary intervention, smoking status, history of CABG, and diabetes duration.*

FDA Label Image

Tica-tabs-fig-17 (Tica Tabs Fig 17)

A Kaplan-Meier curve chart depicting cumulative event rates over days from randomization, comparing Ticagrelor 90 mg tablet to placebo. The y-axis represents cumulative percentage, while the x-axis shows days from randomization up to 34 days. The chart includes event counts and percentages for both groups at specified time points.*

FDA Label Image

Tica-tabs-fig-18 (Tica Tabs Fig 18)

A forest plot depicting hazard ratios (HR) with 95% confidence intervals for various patient characteristics comparing Ticagrelor to placebo. The chart lists subgroups based on age, sex, race, weight, BMI, geographic region, diagnosis of index event, time from event to randomization and loading dose, diabetes, hypertension, prior ischemic events, statin treatment, and smoking status. Data points indicate relative risk with HR below 1 favoring Ticagrelor.*

FDA Label Image

Tica-tabs-structure (Tica Tabs Structure)

Chemical structure of ticagrelor, showing its molecular configuration with multiple rings, hydroxyl groups, and fluorine-containing aromatic rings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.